D-chiro-inositol

View my plan →

The short answer

Studied alone or with myo-inositol for PCOS; optimal ratio and patient-important outcomes remain uncertain.

Evidence and scope: Emerging evidence
This status does not grade the ingredient for every goal, outcome, or person.
Important limitation: Early human findings are hypothesis-generating; efficacy, long-term safety, and optimal dose remain uncertain.
Before deciding: Key concern: Do not assume higher D-chiro doses are better; review pregnancy and glucose medicines.

01 / PRACTICAL GUIDE

Dose, absorption, and combinations

These are indication-specific reference or studied ranges—not a personalized prescription. Start with the objective, then check the form, label, medicines, and health conditions.

Reference range by objective

Glucose-related researchCommon combinations use a 40:1 myo- to D-chiro-inositol ratio; no universal dose

Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.

Dose source ↗

More is not automatically better. A clinician or product label may specify a different amount.

Absorption / solubilityWater-soluble

Water-soluble or readily water-dispersible. This does not mean excess is always harmless.

How it is commonly taken

Use a clearly labeled ratio and coordinate with fertility care.

Do not combine casually

Do not assume higher D-chiro doses are better; review pregnancy and glucose medicines.

Dose and use source ↗

Dose and use links lead to primary or official source material. Search links are discovery tools, not proof that every returned paper applies.

02 / EVIDENCE

What the research says

We keep supportive, mixed, negative, safety, and contextual findings together. The headline never replaces the underlying papers.

1research papers in this ledger

0unique primary studies represented

—unique participants represented

These are audited counts for this JIVANA collection, not search-result totals. Participants are counted once when multiple papers use the same cohort; review papers are not added again to participant totals.

Open the research timelineResearch timeline

Entries are ordered by publication year. A study period appears only when the source reports it.

2024

Mixed or qualifiedPMID 38163998

D-chiro-inositol within the international PCOS guideline evidence review

Potential D-chiro-inositol benefit for ovulation was suggested, while many other outcomes were uncertain or unchanged. The overall evidence was limited and inconclusive; the shared review is not counted again in study or participant totals.

Published: 2024

Study design and methods

Design: Systematic review and meta-analysis of 30 inositol trials; overlapping cross-supplement context
Population: Women with polycystic ovary syndrome
Intervention: D-chiro-inositol alone or within inositol comparisons and combinations
Outcome: Ovulation, reproductive, hormonal, metabolic, and adverse outcomes

Open research record ↗

Unscreened discovery appendix—not evidence29 candidate publicationsSearch run: Aug 21, 2026

Complete for the displayed PubMed query at the search timestamp—not for all databases or every possible synonym. Candidates can be irrelevant, duplicate the same study, or report negative findings. They are never summed as evidence or participants until screened.

03 / SOURCES

Start with the source material

Official evidence overviewPubMed bounded human-evidence search Live PubMed discovery searchNational Library of Medicine

The live search is for discovery only. Search-result counts change and are not included in the audited totals above.

Recent PubMed discovery recordsDirect links to the first 12 records returned by the reproducible search. These are discovery candidates—not reviewed summaries or a count of supportive findings.

04 / EXPERT CONTEXT

Expert context—not evidence

Expert positions are dated context—not scientific evidence. They never raise the evidence status or become consensus by repetition.

No direct, source-verified endorsement is currently recorded. Research authorship or discussion alone is not treated as endorsement.